|
Frovatriptan
resources
|
|
|
|
|
|
DRUG INFO
Frovatriptan
Drug Name:
Frovatriptan
Indication: For treatment of acute migraine headache in adults
Pharmacology: Frovatriptan is a selective 5-hydroxy-tryptamine1 (5-HT1B/1D) receptor subtype agonist, indicated for the acute treatment of migraine attacks with or without aura in adults. Frovatriptan is a 5-HT receptor agonist that binds with high affinity for 5-HT1B and 5-HT1D receptors. Frovatriptan has no significant effects on GABAA mediated channel activity and has no significant affinity for benzodiazepine binding sites.
Mechanism Of Action: Frovatriptan is believed to act on extracerebral, intracranial arteries and to inhibit excessive dilation of these vessels in migraine. Frovatriptan is a 5-HT receptor agonist that binds with high affinity for 5-HT1B and
Drug Category: Anti-migraine Agents; Vasoconstrictor Agents; Anti-inflammatory Agents;
Brand Names/Synonyms: Frova; Frovatriptan; Miguard
Dosage Forms: Not Available
Absorption: The absolute bioavailability of an oral dose of frovatriptan 2.5 mg in healthy subjects is about 20% in males and 30% in females
Interactions:
DrugBank: Interactions for Frovatriptan
Interactions for Frovatriptan:
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Due to a
theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like
dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see CONTRAINDICATIONS).
Concomitant use of other 5-HT1B/1D agonists within 24 hours of FROVA treatment is not
recommended.
Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine,
sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with
5-HT1 agonists. If concomitant treatment with frovatriptan and an SSRI is clinically warranted,
appropriate observation of the patient is advised.
Drug/Laboratory Test Interactions
FROVA is not known to interfere with commonly employed clinical laboratory tests.
Chemical IUPAC Name: 6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
Chemical Formula: C14H17N3O
Half Life: 26 hours
Drug Type: Approved Drug
# Accession No: APRD00270
CAS Registry Number: 158930-17-7
|
|
|
|
|
|
Frovatriptan News
(When available)
Vernalis Successfully Completes Frovatriptan Phase III Open Label ... Dec 20, 2005
PharmaLive.com (press release), Frovatriptan, marketed as Frova(R) in the US by Vernalis' partner, Endo Pharmaceuticals Inc., is a selective 5-HT1B/1D receptor agonist approved as an acute ...
CSFB Reiterates Outperform On Vernalis Dec 20, 2005
New Ratings ...focused and well-incentivised specialist partner for a product that has historically lacked commercial commitment, "and second, the fact that Frova has already ...
NEW AMERICA Dec 29, 2005
Investor's Business Daily (subscription) The drug, Frova, is indicated for acute migraine attacks. Endo plans to seek approval to market Frova for a new indication — menstrual-related migraines. ...
|
|
|
